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Objective: To assess the efﬁcacy and safety of intra-articular hyaluronic acid (IAHA) injection in knee
joints of patients with Kashin-Beck disease (KBD).
Methods: We searched nine electronic databases as well as unpublished data from inception until
November 30th 2013 using a combination of search terms for KBD and hyaluronic acid (HA). For
dichotomous data, odds ratios (OR) and 95% conﬁdence intervals (CI) were estimated. For continuous
data, standard mean difference (SMD) was used for outcomes pooled on the difference scale using a
“random-effects” or “ﬁxed-effects” model. We also compared the mean and standard deviation of
cytokine levels in post-treatment.
Results: The seven eligible trials included 954 IAHA and495 control patients. Themethodological quality of
included trialswas low. Theoverall effectiveness of the IAHAgroupand control groupwere93.7%and62.9%,
respectively. IAHA group resulted in very large treatment effects compared to pre-treatment values in 12
months, with SMD values ranging from1.19e2.64 (all P< 0.05). Compared to controls, SMDs in IAHA group
ranged from 0.19e0.64 at 1 week to 1 month (all P > 0.05) and 0.68e1.47 at 2 months to 12 months (all
P < 0.05). There was signiﬁcant improved of HA, cluster of differentiation44 (CD44), keratan sulfate (KS),
interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) and nitric oxide (NO) contents in serum compared
with that in the post-treatment and healthy control in non-KBD area (all P < 0.05).
Conclusion: IAHA for the treatment of KBD was safe and efﬁcacious at 12 months with low and transient
adverse reactions. However, more high-quality randomized controlled trials (RCTs) are needed to
conﬁrm its therapeutic effect.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Rationale
Kashin-Beck disease (KBD) is a chronic, endemic, deformation
osteoarthropathy with unclear etiology and pathogenesis until
now1e4. Its clinical characteristics are arthralgia, deformation and
limited mobility, and its pathological characteristics are necrosis,
degeneration, and degradation of articular cartilage and growth
plate cartilage. The severe cases show short stature, disability and
even loss of life skills5e7. KBD was widely distributed in 377
endemic counties in China with 642,000 KBD patients diagnosed
in 2011, and a further 37,917,000 individuals at risk according too: X. Guo, School of Public
rsity, No 76 Yanta West Road,
ax: 86-029-82655032.
ternational. Published by Elsevier LChina health statistics yearbook in 20118. An epidemiological
survey estimated that KBD in children have been controlled
effectively. Therefore, the treatment of KBD has attracted greater
attention from Chinese health authorities. Two meta-ana-
lysises9,10 of selenium for the prevention and treatment of KBD in
children concluded that current evidences from randomized
controlled trials (RCTs) and non-RCTs consistently suggested the
beneﬁts of selenium supplementation for prevention and treat-
ment of KBD in children. Furthermore, nonsteroidal antiin-
ﬂammatory drugs (NSAIDs) and steroids11e13, selenium
supplementation14e18, physiotherapy19 and various joint
debridement techniques20e22 can relieve symptoms in short-
term. However they cannot repair cartilage lesion and prevent
disease progression, there is currently no effective treatment for
KBD.
Hyaluronic acid (HA) is one of the main components of artic-
ular cartilage and synovial ﬂuid. Intra-articular hyaluronic acid
(IAHA) has been widely employed in the medical management oftd. All rights reserved.
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considerable controversy. Among the eight meta-analyses and
systematic-reviews performed to date23e30, four trails drew pos-
itive conclusions23e26 that IAHA was an effective and safe treat-
ment for OA. Two trails27,28 had a small effect when compared
with intra-articular placebo, which might have been over-
estimated due to publication bias. But Arrich J29 and Bannuru R
R30 came to the conclusion that IAHA had not been conﬁrmed to
show the beneﬁcial effects. As adult KBD is a speciﬁc type of OA,
the clinical management of KBD may be educated by insights
gained from the management of OA31. Thus, HA has been used to
treat KBD, which showed that HA can markedly improve the
function of the knee and relieve the symptoms of KBD. However,
to date no systematic review of the relevant data has been
conducted.
Objectives
The objective of this meta-analysis is to synthesize the results
from included studies, to assess the efﬁcacy of IAHA for the treat-
ment of KBD; to compare the effectiveness of the treatment for KBD
and OA; and to determine the changes in cytokine levels in adult
KBD in the pre-and post-treatment. This meta-analysis aims to
assess whether the published evidence justiﬁes the use of IAHA in
KBD.
Materials and methods
We conducted this meta-analysis complied with the PRISMA
(Preferred Reporting Items for Systematic reviews and Meta-Ana-
lyses) statement32 as closely as possible, the aim of the PRISMA
Statement is to help us report a meta-analysis to assess the beneﬁts
of IAHA for KBD.
Eligibility criteria
We included RCTs comparing the efﬁcacy of IAHA with vitamin
C, drugs or other treatment for the treatment of KBD in adult more
than 18 years of age. Every included study should contain extract-
able data for at least one of the outcome measures (Table I) and a
report for KBD clinical trials. KBD had to have been diagnosed by
clinical and X-ray diagnosis criterion (GB 16003-1995)33. In this
meta-analysis all trials included were required to have more than 1
month’s follow-up. Non-standard outcomemeasures and duplicate
published articles were excluded.
Information sources
We carried out a search of all publications between inception
and November 30th, 2013 using nine electronic databases, which
included Google scholar, ISI Web of knowledge, Medline, Springer
Link, Cochrane Controlled Trial Register, Chinese National Knowl-
edge Infrastructure (CNKI), Chinese Science and Technique Journals
Database (VIP), The Chinese Biomedical Database (CBM) and Wan
Fang data. All dates and languages were included.Table I
Hierarchy of outcome measures
1. Global knee pain score (visual analog or Liken scale)
2. Lequesne index
3. The Western Ontario and McMaster Universities Arthritis Index (WOMAC)
4. Function score for index joint (visual analog or Liken scale)
5. Overall response rate (WS/T79-1996, WS/T79-2009)Search strategy
The key search terms of “Kashin-Beck disease” or “KBD” or
“Urov” and “hyaluronic acid” or “hyaluronan” or “hyaluronate” or
“HA” both in English and Chinese were used with the restricted
language of English and Chinese respectively, and all searches were
limited to human clinical trials. We also searched the references of
review cited for additional articles by hand. Unpublished and
ongoing trials were added by contacting the authors.
Study selection
Eligibility of studies was identiﬁed independently by two re-
viewers (CT Xia and H Fang) in three stages. Firstly, title and ab-
stracts from all search results were screened for eligibility in
duplicate. Secondly, studies were excluded if title and/or abstract
had an obvious violation of the inclusion criteria. The lastly, full-
text articles were obtained for all studies matching the inclusion
criteria or with unclear eligibility. Any disagreement was resolved
by consensus, if necessary, with the help of the senior authors
(X Guo).
Data collection process
Two reviewers (CT Xia and H Fang) extracted data from each
trial in duplicate and entered into a predeﬁned datasheet. And then
the third investigator (FF Yu) checked data consistency, any
discrepancy identiﬁed was discussed until consensus.
Data items
Data was extracted using structured data extraction tables
including the contents: trial design, inclusion and exclusion
criteria, subject’s general data, characteristics of HA, usage of HA
and controls, lost to follow-up, the outcome measures of effect
(mean, standard deviation and effective rate). If research literature
did not include the exact data, we consulted the original author by
e-mail.
Methodological quality evaluation
The risk of bias of included studies was accessed using the Jadad
score34 with the following items: (1) reporting of a randomization
method, (2) allocation concealment, (3) blinding method, and (4)
completeness of follow-up (Table II). And then the risk of bias was
divided into low and high grades by Jadad score. The quality
assessment was carried out independently by two researchers
(CT Xia and H Fang) with parallel cross check. Any disagreement
was resolved by consensus (FF Yu) (Table III).
Data synthesis
Data analysis was performed using StataSE version 11 (STATA
Corp, College Station, TX). For non-continuous variables results we
used odds ratios (OR) and 95% conﬁdence intervals (CI) for the ef-
fect size according to the intention-to-treat (ITT) principles. For
continuous variables we used the standard mean difference (SMD)
and 95% CI for the effect size in each time window: (1) pre-
treatment to post-treatment SMD for IAHA and (2) SMD for IAHA
vs controls. For reference, SMD values of 0.2, 0.5, 0.8, and 1.0 are
deﬁned as small, medium, large, and very large, respectively35. The
pooled effect was ﬁrst calculated at each time point separately
using a random effects model with the DerSimonian-Laird
method36. We used forest plots with 95% CI to present the pooled
data. And then the “random-effect” model was used to take meta-
Table II
Characteristics of included trials
Studies Case
number
(I/C)
Average
age (years)
Sex
(male/
female)
Intervention (I) Control (C) Outcome
measurement
Follow-up
Xu et al. 200438 50/40 49.7  6.8 47/43 HA (Qi sheng Pharm. Corp, Shanghai) 2.5mL
(3.75 mg), 1200 w 2400 kDa; total of two
injections, one injection per wk
0.1 g Vc; total of 1
month, three times
a day
Lequesne 6 months
Yu et al. 201139 565/189 52.8 (28e84) 462/292 Arthroscopic debridement þ HA (Qi sheng
Pharm. Corp, Shanghai) 2.5 mL (3.75 mg),
1200 w 2400 kDa; total of ﬁve injections,
one injection per wk
Arthroscopic
debridement
Lequesne 18 months
Tang et al. 201240 80/82 62.89  12.25 66/96 HA (Jing Feng Pharm. Corp, Shanghai)
2.5 mL (2.5 mg), 600 w 1500 kDa; total of
three injections, one injection per wk
7.5 mg meloxicam
once daily for 12
weeks
WOMAC, VAS 3 months
Yu et al. 201341 50/49 56.93  7.66 36/63 HA (Qi sheng Pharm. Corp, Shanghai) 2.5mL
(3.75 mg), 1200 w 2400 kDa; total of four
injections, one injection per wk
Oral starch tablets
for 3 months
contumely
WS/T79-2011
(Lequesne)
48 months
Liu et al. 201142 106/50 50 (35e65) Unclear HA (Qi sheng Pharm. Corp, Shanghai) 2.5mL
(3.75 mg), 1200 w 2400 kDa; total of four
injections, one injection per wk
Vitamin C WS/T79-1996,
VAS and HA,
NO, IL-1B,
TNF-a
6 months
He et al.201143 41/22 52.06  13.85 36/30 HA (Qi sheng Pharm. Corp, Shanghai) 2.5mL
(3.75 mg), 1200 w 2400 kDa; total of ﬁve
injections, one injection per wk
Unclear NO, IL-1B,
TNF-a
5 weeks
He et al.201144 63/63 54.73  7.19 27/36, HA (Qi sheng Pharm. Corp, Shanghai) 2.5mL
(3.75 mg), 1200 w 2400 kDa; total of four
injections, one injection per wk
Unclear HA, CD44, KS 4 weeks
Abbreviation: I ¼ intervention, C ¼ control, wk ¼ week.
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I2>50%); or else a “ﬁxed-effect” approach was used. Of which the I2
statistic was used to estimate heterogeneity of treatment effects
with values of 25%, 50%, and 75% representing low, moderate,
and high inconsistency, respectively37. A sensitivity analysis was
not done to assess the robustness of the results for primary
outcome as the number of identiﬁed trials was less than nine
studies. The signiﬁcance level of two-sided test was P < 0.05.
We also computed the pooled effect size for changes in cytokine
levels of HA, cluster of differentiation44 (CD44), keratan sulfate
(KS), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) and
nitric oxide (NO) using pre-treatment and post-treatment means
and standard deviation. We compared the difference in cytokine
levels among pre-treatment, post-treatment, healthy control in
KBD area and healthy control in non-KBD area using t test. The
signiﬁcance level of two-sided test was P < 0.05.
Results
Study selection
Our search yielded 209 studies, of which 65 duplicate studies
were excluded. We excluded 130 studies after reading title and
abstract for preliminary screening. We read through the 14Table III
Methodological quality of included trials
Author (year) Generation
of random
sequence
Allocation
concealment
Blinding
method
Loss to
follow-up
(%)
ITT
Xu et al., 200438 UC UC NM Y (3.3%) Not used
Yu et al., 201139 UC UC NM N (0%) Y
Tang et al., 201240 Y Y S Y (13%) Y
Yu et al., 201341 Y Y S Y (2%) Not used
Liu et al., 201142 UC UC NM N (0%) Y
He et al., 201143 UC UC NM Y (34%) Not used
He et al., 201144 UC UC NM N (0%) Not used
Abbreviation: UC ¼ unclear, NM ¼ not mention, N ¼ no, Y ¼ yes, S ¼ single-blind.remaining full-text studies, and seven of these studies were
excluded since they did not meet the inclusion criteria. Finally, we
included seven clinical trials with 1449 unique subjects (IAHA: 954,
control: 495)3844. Therapeutic effects were reported in four of the
included studies which covered one unpublished study41, two
studies43,44 reported the changes in cytokines levels in post-
treatment, and one study42 covered both therapeutic effect and
changes in cytokine levels (Fig. 1).
Study characteristics
The characteristics of the seven included trials from 2004 to
2013 were presented in Table II. Therewere ﬁve RCTs included 1261
participants that reported therapeutic effects, which 851 subjects
were given the IAHA treatment and 410 subjects were assigned as
control group. There were three trials included 345 participantsFig. 1. Flow of articles through the meta-analysis.
Fig. 2. Show a forest plot for OR in the overall effectiveness for IAHA injection vs
controls.
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Overall, the average age was 53.85 years in the seven studies.
Males accounted for 54.6% of the population in the six trials, but
one trial42 was unclear on the gender distribution of their popu-
lation. The 2.5 mL (3.75 mg) HA used in six trials38,39,41e44 was
provided by Shanghai Qi sheng Pharmaceutical Co., Ltd, and in oneFig. 3. Show a forest plot for SMD in the IAHA efﬁcacy vs pre-treatment attrials40 the 2.5 mL (2.5 mg) HAwas provided by Shanghai Jing Feng
Pharmaceutical Co., Ltd. The total number of injections received by
patients ranged from 2 w 5 (Table II). The outcome measurement
systems included Lequesne, WOMAC, VAS, WS/T79-1996 and WS/
T79-1996, the SMD calculated by the different measurement
systems.
Risk of bias within studies
Only one trial40 described generation of random sequence and
allocation concealment, and were classiﬁed as a high-quality study.
The remaining studies were deﬁned as low quality as extent of
generation of random sequence and allocation concealment were
unclear. Two of the seven trials adopted single-blind assignment,
and three of the seven trials adopted ITT. The loss to follow-up in
the ﬁve RCTs was 5.5%.
The overall effective rate
Five trials (851 IAHA, 410 Controls) contributed to the meta-
analysis of the overall effective rate. The pooled OR (95% CI) was
10.44 (3.57 w 30.51) favoring HA, with an I2 score of 86.2% and
P < 0.001, and the “ﬁxed-effect” model was used to take meta-
analysis. The effectiveness of the IAHA group and control group
were 93.7% and 62.9% respectively, which indicated a signiﬁcant
difference in efﬁcacy between the IAHA group and control group
(Z ¼ 4.29, P < 0.001) (Fig. 2).1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months.
F.F. Yu et al. / Osteoarthritis and Cartilage 22 (2014) 718e725722IAHA efﬁcacy vs pre-treatment
IAHA injection resulted in very large treatment effects for the
index of the knee joint compared to pre-injection values from 1
week to 12 months. The SMD for index of the knee joint was 1.22 at
1week, 2.50 at 1months, 2.64 at 2months, 2.30 at 3months,1.42 at
6 month, 1.19 at 12 months and 1.67 overall (both P < 0.05) (Fig. 3).
There was high heterogeneity (I2 ¼ 92.8%e97.6%, all P < 0.001) for
IAHA treatment effect at 1 week, 6 months, 12 months and overall,
but at 3 months there was moderate heterogeneity (I2 ¼ 51.3,
P ¼ 0.128), and at 1 month and 2 months there was no explainable
heterogeneity (I2 ¼ 0, both P > 0.4). However treatment effects for
the index of the knee joint were slighter lower with SMD of 0.99 at
2 weeks (P ¼ 0.124), there was no statistically signiﬁcant difference
compared to pre-injection. The overall trend rose ﬁrst and then fell
as the treatment time gone on.
IAHA efﬁcacy vs controls
We got four comparisons including 745 intervention and 360
controls. At 1 week, 2 weeks and 1 month, the SMD (95% CI) for
index of the knee joint was 0.36 (0.73 to 1.46), 0.19 (0.30 to 0.67)
and 0.64 (0.11 to 1.38), which was unfavorable of IAHA
(Z ¼ 0.65 w 1.66, all P > 0.05), and there was high heterogeneity
(I2¼ 87.9%w 95.8%, all P< 0.001). However, at 2months, 3 months,
6 months, and 12 months, the SMD (95% CI) for index of the kneeFig. 4. Show a forest plot for SMD in the IAHA injection vs controls at 1joint was 0.95 (0.58e1.33), 1.47 (0.60e2.34), 1.25 (0.01e2.49) and
0.68 (0.51e0.84), the SMD in favor of IAHA (Z ¼ 1.97 w 7.38, all
P < 0.05), and there was middle heterogeneity (I2 ¼ 50.9%,
P ¼ 0.154) at 2 months, high heterogeneity (I2 ¼ 92% w 97.1%,
P < 0.001) at 3 months, 6 months, and 12 months. In all, the SMD
(95% CI) in IAHA injection group was 0.79 (0.49e1.09), there was
high statistical heterogeneity (I2 ¼ 94.0%, P < 0.001), the reduction
of SMD for the index of the knee joint has been proved clinically
effective (Z ¼ 5.15, P < 0.001) (Fig. 4).
Changes in cytokine levels
Three trials reported the changes in cytokines levels in the KBD
group, healthy controls in KBD and non-KBD area. The levels of
CD44 and KS in the serum of healthy control in KBD area were not
acquired. HA in serum was detected by competitive radioimmu-
noassay and enzyme-linked immunosorbent assay (ELISA), ELISA
was also used to detect the levels of CD44, KS, IL-1b and TNF-a in
serum, the levels of NO were measured by using nitrate reduction
method. There was signiﬁcant reduction of HA, CD44, KS, TNF-a
and NO in serum in post-treatment, healthy controls in KBD area
and non-KBD area (both P < 0.05), and the signiﬁcant reduction of
IL-1b in pre-treatment compared with post-treatment and healthy
controls in non-KBD (both P < 0.05). Meanwhile, no signiﬁcant
difference the levels of IL-1bwere observed between pre-treatment
and healthy controls in KBD area (P > 0.05) (Table IV).week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months.
Table IV
The changes in cytokine levels in the pre-and post-treatment
Groups HA (ng/ml) CD44 (umol/L) KS (ng/ml) IL-1b (ng/ml) TNF-a (pg/ml) NO (umol/L)
KBD group Pre-treatment 485.07  272.53(63) 594.93  199.53(63) 713.73  250.02(63) 21.15  6.83(147) 26.69  8.96(147) 85.75  31.76(147)
Post-treatment 357.73  274.90(63)** 349.69  100.73(63)* 416.56  161.09(63)* 13.08  5.55(41)* 8.70  2.96(41)* 21.36  9.98(41)*
Healthy control in KBD area 90.55  18.25(96)* e e 21.03  6.63(118) 22.90  4.88(118)* 37.05  13.03(118)*
Healthy control in non-KBD area 56.53  60.22(63)* 299.88  92.04(63)* 274.81  84.80(63)* 11.64  4.12(25)* 6.32  1.71(25)* 10.22  6.29(25)*
Pre-treatment compared with post-treatment, healthy control in KBD area and non-KBD area, **P < 0.05, *P < 0.01.
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The ﬁve RCTs with a total of 848 intervention patients reported
26 cases of joint pain and swelling after injection, in which the
symptoms disappeared after 1 week without special treatment.
One study mentioned two cases of joint effusion and one case of
injection site bleeding. We didn’t count the adverse reactions in the
control group due to inconsistencies. Overall the rate of adverse
events in IAHA groups was 3.1%.Discussion
Summary of evidence
Numerous systematic reviews and meta-analyses have been
published on the safe and effective of IAHA for the treatment of
knee OA over the last decade, with the SMD of IAHA vs control
group for efﬁcacy outcomes ranging from 0.0 w 0.4623e30. How-
ever, no authors have carried out a systematic review of IAHA for
the treatment of KBD in adults. This prompted us to conduct this
meta-analysis of IAHA in this patient population. For comparison,
the SMD of IAHA in knees for adults KBD ranged from 0.99w 2.64
compared to pre-treatment, 0.19 w 1.47 compared to controls,
depending on outcome and time window. This statistic suggests
that the overall treatment effect of IAHA for KBD was distinctly
better than that obtained from OA clinical trials. There was a
distinct difference between a pre-to-post treatment effect and
controls treatment effect, the former assesses the overall patient
experience in the IAHA group while the latter teases out the in-
dependent effect of IAHA above and beyond that of arthroscopic
debridement, vitamin C, and meloxicam. Thus, the efﬁcacy results
of IAHA for KBD can be best characterized by a very large treatment
effect on index of the knee joint from 1 week to 12 months,
comparing to pre-treatment, and from small to large treatment
effect with IAHA comparing to controls during this same period.
Therefore, IAHA treatment of KBD has better clinical application
prospect than that of OA.
The role of cytokine-mediated in the development of joint dis-
ease is becoming more and more attention recently. In this meta-
analysis showed that the levels of HA in serum decreased in the
post-treatment, but did not reach the level of the healthy controls
in both KBD and non-KBD areas, and indicated that IAHA treatment
had an inﬂuence on glycan from cartilage matrix protein, but with
limited therapeutic effect. After intra-articular injection of HA, the
cytokine levels of HA, CD44, KS, TNF-a and NO signiﬁcantly
improved compared with pre-treatment, which did not up to the
level of the healthy control in non-KBD areas. The level of IL-1bwas
signiﬁcantly decreased in the post-treatment and healthy control in
non-KBD area compared with that in the pre-treatment, which
reached the level of the healthy control in non-KBD areas. Mean-
while, no difference on the level of IL-1b was observed between
pre-treatment and healthy control in KBD area. Therefore, IAHA
treatment for KBD could be by lowering levels of inﬂammatory
factors in serum, and may play suppress inﬂammation, protect andrepair of articular cartilage function, but need to further study its
biological mechanisms.
Limitations
Our meta-analysis has several limitations that may inﬂuence
interpretation. Firstly, the trial we selected did not consider a
saline-control for ethical reasons. Therefore the results may have
been overestimated due to the unreasonable control. Secondly,
IAHA had a small effect within 1month thatmay be associatedwith
adverse reactions, which resolved spontaneously. Thirdly, the
overall methodological quality of the seven included trials was low.
The ﬁve trials don’t mention allocation concealment, generation of
random sequence and the generation of random sequence was
unclear, only two studies used single-blinding. Five of included
trials insufﬁciently assessed the baseline characteristics of partici-
pants (e.g., age, gender, bodymass index and KBD stage, etc). Lastly,
small sample sizes, inconsistent dosages and various quality levels
of the studies also could weaken the validity of the results.
Conclusions
In summary, the therapeutic effect of IAHA for KBD is safe and
efﬁcacious with low adverse advents, which distinctly better than
that obtained from OA clinical trials. IAHA injection in knee joints
for KBD could be signiﬁcantly lower the levels of HA, CD44, KS, IL-
1b, TNF-a and NO in serum in post-treatment, their content can be
used as one of KBD therapeutic effect evaluation index. In order to
obtain sufﬁcient and reliable evidence to support the effectiveness
of HA for treating KBD, further well designed RCTs are needed to
carry out.
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